Aptevo Therapeutics (APVO) Revenue & Revenue Breakdown
Aptevo Therapeutics Revenue Highlights
Main Segment (Y)
Product
Main Geography (Y)
Product
Aptevo Therapeutics Revenue by Period
Aptevo Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $3.11M | -74.67% |
| 2021-12-31 | $12.29M | 185.26% |
| 2020-12-31 | $4.31M | -86.71% |
| 2019-12-31 | $32.42M | 40.56% |
| 2018-12-31 | $23.07M | 57.37% |
| 2017-12-31 | $14.66M | -59.77% |
| 2016-12-31 | $36.43M | 8.43% |
| 2015-12-31 | $33.60M | -26.36% |
| 2014-12-31 | $45.63M | 26741.76% |
| 2013-12-31 | $170.00K | - |
Aptevo Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Aptevo Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $902.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $-3.11M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $3.11M | -15.03% |
| 2021-12-31 | $3.67M | 18.38% |
| 2021-09-30 | $3.10M | -0.45% |
| 2021-06-30 | $3.11M | 28.46% |
| 2021-03-31 | $2.42M | 2.02% |
| 2020-12-31 | $2.37M | 62.20% |
| 2020-09-30 | $1.46M | 209.30% |
| 2020-06-30 | $473.00K | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $9.03M | 0.22% |
| 2019-09-30 | $9.01M | 22.43% |
| 2019-06-30 | $7.36M | 4.81% |
| 2019-03-31 | $7.02M | 10.65% |
| 2018-12-31 | $6.35M | 8.96% |
| 2018-09-30 | $5.82M | -14.68% |
| 2018-06-30 | $6.83M | 67.67% |
| 2018-03-31 | $4.07M | 44.46% |
| 2017-12-31 | $2.82M | -54.34% |
| 2017-09-30 | $6.17M | -42.66% |
| 2017-06-30 | $10.76M | 45.28% |
| 2017-03-31 | $7.41M | -15.51% |
| 2016-12-31 | $8.77M | -6.76% |
| 2016-09-30 | $9.40M | -7.73% |
| 2016-06-30 | $10.19M | 26.35% |
| 2016-03-31 | $8.07M | -2.64% |
| 2015-12-31 | $8.29M | 26.27% |
| 2015-09-30 | $6.56M | -7.45% |
| 2015-06-30 | $7.09M | -39.21% |
| 2015-03-31 | $11.66M | - |
Aptevo Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Aptevo Therapeutics Revenue Breakdown
Aptevo Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 19 | Dec 18 |
|---|---|---|
| Product | $32.40M | $23.07M |
Aptevo Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 19: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|
| Product | $6.35M | $5.82M | $6.83M |
Aptevo Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 18: Product (100.00%).
Aptevo Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 | Dec 18 |
|---|---|---|
| Product | $32.40M | $23.07M |
Aptevo Therapeutics's latest annual revenue breakdown by geography, as of Dec 19: Product (100.00%).
Quarterly Revenue by Country
| Country | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|
| Product | $6.35M | $5.82M | $6.83M |
Aptevo Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 18: Product (100.00%).
Aptevo Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KRON | Kronos Bio | $6.29M | $2.37M |
| NTRB | Nutriband | $2.09M | $645.80K |
| ADXN | Addex Therapeutics | $1.61M | $235.00K |
| LGVN | Longeveron | $709.00K | $468.00K |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| REVB | Revelation Biosciences | - | - |
| PASG | Passage Bio | - | - |
| RNXT | RenovoRx | - | - |
| ACHL | Achilles Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| HOTH | Hoth Therapeutics | - | - |
| NRBO | NeuroBo Pharmaceuticals | - | - |
| APVO | Aptevo Therapeutics | - | - |
| ATXI | Avenue Therapeutics | - | - |
| CYCN | Cyclerion Therapeutics | - | $194.00K |
| QNRX | Quoin Pharmaceuticals | - | - |
| IVVD | Invivyd | - | - |